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Introduction: There is much interest in the use of noninvasive bio-
markers in the management of lung cancer, particularly with respect 
to early diagnosis and monitoring the response to intervention. Cell-
free tumor DNA in patients with cancer has been shown to hold 
potential as a noninvasive biomarker, in which the response to treat-
ment may be evaluated using a blood test only. Multiple technologies 
have been suggested as being appropriate to measure cell-free tumor 
DNA. Microdroplet digital polymerase chain reaction (mdPCR) has 
a number of attributes that suggest it may be a useful tool for detect-
ing clinically relevant genetic events. It offers precise and accurate 
quantitation of mutant alleles, including rare variants.
Methods: We evaluate the performance of mdPCR in the analysis of 
DNA extracted from reference standards, tumor biopsies, and patient 
plasma.
Results: The potential of mdPCR to detect clinically relevant muta-
tions is demonstrated, in both formalin-fixed paraffin-embedded 
material and plasma. Furthermore, we show that mdPCR can be used 
to track changes in peripheral blood biomarkers in response to treat-
ment and to detect the emergence of drug-resistant clones.
Conclusions: MdPCR has potential as a tool to detect and quantify 
tumor-derived mutational events in cell-free DNA from patients with 
lung cancer.
Key Words: Droplet digital polymerase chain reaction, Circulating 
DNA, Liquid biopsy.
(J Thorac Oncol. 2015;10: 212–217)
Lung cancer is characterized by a grossly altered genomic landscape.1 A number of mutations occur at high preva-
lence in lung cancer, including mutations in EGFR and KRAS,2 
and these are now routinely evaluated on diagnosis as part of 
a standard clinical assessment.
It is possible to detect tumor DNA noninvasively in 
peripheral blood (cell-free tumor DNA [ctDNA]). This was 
originally inferred by the measurement of total cell-free DNA 
(cfDNA) and the demonstration that patients with cancer 
tended to have higher cfDNA.3 Latterly, a number of groups 
have demonstrated that it is possible to detect specific muta-
tional events, or circulating nucleic acid biomarkers, in lung 
and other solid organ malignancies.4
The ability to detect tumor-specific DNA in the periph-
eral blood raises the possibility of applying so-called “liquid 
biopsies” to the routine management of patients with lung can-
cer. The potential advantages are both broad and significant. 
The ability to specifically detect mutational events in a diag-
nostic specimen will facilitate longitudinal studies in which 
peripheral blood is resampled at intervals to assess the mutant 
allele “load.” CtDNA could be used to monitor the response 
to therapeutic intervention and to detect relapse before clinic-
radiological manifestations.5 Further possibilities include the 
potential to direct therapeutic decisions based on the analysis 
of ctDNA. This may include the identification of subclonal 
populations with mutations that confer resistance to specific 
therapeutic agents; or the decision to withdraw or alter a thera-
peutic strategy based on an incremental rise in ctDNA despite 
treatment.4,6
A number of platforms have been suggested for this 
approach, each with specific attributes.7,8 Digital polymerase 
chain reaction (PCR) has a number of characteristics that make 
it particularly attractive for the analysis of ctDNA.9 Digital 
PCR relies on the ability of PCR to detect a single copy of a 
locus (mutant allele) of interest if present in a reaction vol-
ume. The quantitation relies on a DNA sample being diluted 
so that partitioned digital PCR reactions (in microdroplets 
or reaction wells) may or may not contain the locus of inter-
est. The absolute number of copies of a particular locus in a 
given sample of DNA can then be directly estimated from the 
number of positive droplets. In a number of studies, includ-
ing those in which circulating biomarkers have been analyzed, 
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digital PCR has been demonstrated to be more precise and 
accurate than quantitative PCR, particularly when template 
DNA is dilute.10,11
Microdroplet digital PCR (MdPCR) is a form of 
digital PCR in which the “partitions” are microdroplets. In 
each single reaction up to 15,000 to 20,000 microdroplets 
are created.12 The protocol is simple, economic, and it uses 
readily available, standard, fluorescently labelled locus-
specific probes. Together with the general advantages of 
digital PCR, these attributes make mdPCR ideally suited to 
the analysis of ctDNA, in which the target is generally pres-
ent at a low mutant allele frequency (MAF) in an excess of 
wild-type cfDNA.
In this study, we demonstrate that mdPCR can be used 
to detect and quantify ctDNA with high specificity in plasma 
from patients with lung cancer. We further demonstrate that 
it can be used to detect and quantify mutations in diagnos-
tic specimens, track the response to treatment, and detect the 
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FIGURE 1.  Validation of probes using reference 
DNA. The absolute number of copies of the EGFR 
locus was estimated in cell line DNA from cell 
lines known to have specific genotypes—H1975 
(WT KRAS, mut EGFR); H23 (mut KRAS—G12C, WT 
EGFR). For each locus (A–C), increasing concentra-
tions of mutant DNA from a cell line were assayed in 
a consistent background of 3000 copies of wild-type 
DNA. Experiments were performed in triplicate and 
are presented as the mean ± SD. For G12R (D) and 
EGFR exon 19 deletion, increasing volumes of a 
commercially available reference standard was used 
to establish efficacy of detection in an excess of WT 
molecules.
TABLE 1.   Experiments to Establish Threshold Values for a Positive Assay
Patient Genotype Test Probe +mut +wt MAF Threshold for +ve
EGFR KRAS
8 WT G12C EGFREx19del 0 1585 0 ≥1
23 WT WT EGFREx19del 0 3997 0 ≥1
31 WT WT EGFREx19del 0 726 0 ≥1
33 WT WT EGFREx19del 0 1068 0 ≥1
8 WT G12C* EGFRT790M 0 179 0 >1
12 WT WT EGFRT790M 0 544 0 >1
17 WT G12V* EGFRT790M 0 960 0 >1
23 WT WT EGFRT790M 1 4649 0.0002 >1
29 WT G12A EGFRT790M 1 2746 0.0004 >1
31 WT WT EGFRT790M 0 904 0 >1
33 WT WT EGFRT790M 1 576 0.002 >1
12 WT WT KRAS G12C 0 216 0 >1
23 WT WT KRAS G12C 1 4486 0.0002 >1
31 WT WT KRAS G12C 1 1224 0.0008 >1
32 WT WT KRAS G12C 0 585 0 >1
12 WT WT KRAS G12R 0 602 0 ≥1
23 WT WT KRAS G12R 0 5559 0 ≥1
31 WT WT KRAS G12R 0 738 0 ≥1
32 WT WT KRAS G12R 0 88 0 ≥1
33 WT WT KRAS G12R 0 572 0 ≥1
Establishing probe specificity. The primer/probes were tested against the equivalent of 500 μl of plasma DNA extracted from enrollment (pretreatment) bloods. Patients were 
selected if their diagnostic biopsy was genotyped as negative for the corresponding mutation. * indicates lower volume plasma used.
MAF, mutant allele frequency; WT, wild type .
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emergence of resistance-conferring mutations in the periph-
eral blood.
PATIENTS AND METHODS
Subjects and Clinical Specimens
Patients with stage IIIb/IV adenocarcinoma of the lung 
were recruited from the lung oncology clinic at our UK can-
cer center. Three patients who had mutations in EGFR or 
KRAS, and in whom serial blood samples were available, were 
selected for the analysis.
Serial blood samples were collected and plasma prepared 
as per the National Institutes of Health guidelines.13 Aliquots 
were stored at −80°C until further processing. CfDNA was 
extracted from frozen plasma using the QIAamp Circulating 
Nucleic Acid kit (Qiagen, Manchester, UK).
DNA was extracted from formalin-fixed paraffin- embedded 
blocks and cell lines using the DNeasy Blood and Tissue Kit 
(Qiagen). For control DNA, including positive controls for EGFR 
exon 19 deletion (ex19del) and KRAS G12R, a commercially 
available reference standard was used (Horizon Diagnostics, 
Cambridge, UK).
Microdroplet Digital PCR
Details of mdPCR are published and summarized in the 
Supplementary Information (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A703). All reactions were prepared 
using the ddPCR Supermix for probes (BioRad, Hertfordshire, 
UK). Details of cycling conditions are documented in 
Supplementary Information (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A703).
Results were “read” using the QX100 optical reader and 
processed using QuantaSoft (BioRad) software. Each droplet was 
scored as positive or negative based on the relative fluorescence 
intensity in a FAM or VIC/HEX channel. The number of positive 
microdroplets was then recorded. The detail of scoring of micro-
droplets is in the Supplementary Information (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A703).
Absolute concentrations of DNA for each sample were 
estimated using mdPCR assays for reference genes RNaseP 
(RPPH1) and FTH1.
Primers/Probesets
All assays used were purchased directly from BioRad 
except for RNaseP (gene RPPH1), FTH1, and EGFR exon 19 
deletion (Life Technologies, Grand Island, NY). Of note the 
Life Technologies’ exon 19 deletion probe (Assay Reference 
Hs00000228_mu; Life Technologies) detects 19 separate exon 
19 deletions from c.2235 to c.2258 including all of the com-
monly reported variants. Details of all probesets used are in the 
Supplementary Information (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A703).
RESULTS
First, we tested the ability of mdPCR to detect and quantify 
specific mutant alleles in an excess of wild-type DNA. Clinically 
relevant mutant alleles were tested including activating EGFR 
mutations: ex19del and L858R, the resistance-conferring muta-
tion EGFR T790M, and various activating mutations in KRAS 
including G12R and G12C. In each case, the expected linear 
relationship between the number of copies predicted and the 
number of copies detected was observed (Fig. 1).
If an assay is to be used to detect rare variants in plasma, 
then a key performance variable is the false-positive rate in 
plasma-derived DNA. Patients with genotyped tumors that 
were negative for specific mutations were chosen as  “negative” 
controls. For each patient, it was impossible to be certain a 
priori that the specific mutation of interest was truly absent in 
A B
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FIGURE 2.  Patient 11. A, B, Analysis 
of serial plasma samples dem-
onstrates a rapid fall in absolute 
numbers of EGFR exon 19 mutational 
events and MAF. C, The absolute 
numbers of copies of two reference 
autosomal loci are also shown and 
are noninformative when compared 
with the specific assay. D, By month 
6, the exon 19 deletion was again 
detectable, and by month 10 T790M 
was detected for the first time in the 
peripheral blood. Serial CT scans on 
commencing treatment, after cycle 
3 and on progression are shown (E) 
and demonstrate an initial partial 
response of the assumed primary 
(open arrow). This lesion did not 
increase in size but new pulmonary 
nodules appeared consistent with 
progressive disease. MAF, mutant 
allele frequency; CT, computed 
tomography.
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either the primary tumor or the peripheral blood. In each case, 
a threshold value for the limit of detection of the assay was 
established that depended on the number of positive events 
detected per 500 µl of plasma in a series of control plasmas. 
For ex19del, no positive events were detected in control sam-
ples. A positive result was therefore defined as any result with 
more than one positive microdroplet per 500 µl. For KRAS 
G12R, KRAS G12C, and EGFR T790M, a maximum of 0, 1, 
and 1 events were detected per 500 µl of plasma respectively. 
The performance characteristics of each assay are summa-
rized in Table 1.
We proceeded to test the performance of these assays in 
patients with lung cancer that had been genotyped as part of 
their clinical standard-of-care and shown to have mutations in 
KRAS or EGFR. Three patient cases are presented to illustrate 
including a patient with an activating mutation in KRAS and 
two with EGFR mutations.
Case 1
Patient 11 presented with advanced non–small-cell 
lung cancer (adenocarcinoma, T3N3M1b) with metastases to 
bone and brain. Genotyping revealed an activating deletion in 
EGFR exon 19 (18 base pairs deletion, c.2240–2257 del18). 
Erlotinib was commenced and resulted in a marked clinical 
improvement and a partial response on Response Evaluation 
Criteria in Solid Tumors criteria. DNA was extracted from 
both the diagnostic biopsy specimen and serial plasma samples 
(Fig. 2A–C). The deletion was readily detected in the diagnos-
tic biopsy using mdPCR at a MAF of 33% (Supplementary 
Figure 1, Supplemental Digital Content 2, http://links.lww.
com/JTO/A704). Serial testing for the T790M mutation was 
negative until month 11, although an increase in the exon 19 
deletion was noted in month 6. The patient had no symptoms 
suggestive of relapse, but subsequent imaging confirmed pro-
gressive disease (Fig. 2D, E).
Rebiopsy
Month 0      12    13 17    18 20 
Progressive 
disease
Diagnosis
Gefitinib
Paclitaxel/Carboplatin
Afatinib
A
B C
FIGURE 3.  Patient 5. This patient’s treatment course is illustrated. He was recruited to the study in month 17 after discontinu-
ing paclitaxel and carboplatin (A). EGFR ex19del re-emerged in the peripheral blood a month later. For this assay, separate FAM-
labelled probes for the mutation (upper panel) and wild type (lower panel) were used in separate reactions (Life Technologies, 
EGFR_6240_wt/mu) (B). Subsequent analysis of a rebiopsy using mdPCR (C) demonstrated a T790M mutation at a MAF of 17% 
(upper panel) and this mutation was detected in the peripheral blood at month 20 to 2 months after afatinib was discontinued. 
Of note, the T790M mutation was also detected at month 19, but at a very low MAF. These data illustrate how circulating bio-
markers may be useful to guide treatment decisions in patients on complex therapeutic regimes. In (C) two differently labeled 
probes are tested in a single reaction (BioRad), one to detect the mutation (FAM label—blue) and the other to detect the wild-
type allele (HEX label—green). mdPCR, microdroplet digital polymerase chain reaction; MAF, mutant allele frequency.
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Case 2
Patient 5 presented with advanced non–small-cell lung 
cancer with bone metastases (adenocarcinoma, T4N3M1b). An 
activating mutation in exon 19 of EGFR (c.2235_2249 del15) 
was detected on the diagnostic endobronchial biopsy. Gefitinib 
was prescribed with initial effect, but there was clinical and 
radiological progression by month 13. This prompted a rebiopsy 
of a cervical lymph node and second-line treatment (carboplatin/
paclitaxel), which had to be discontinued after 3 months because 
of toxicity (Fig. 3). At this point (month 17), the patient was 
enrolled in the current study. Third-line afatinib was introduced 
at month 18 but discontinued because of clinical progression.
The ex19del was undetectable in the first available plasma 
at month 17 after four cycles of carboplatin/paclitaxel, but after 
only 1 month off chemotherapy was detectable at a MAF of 
7% (Fig. 3B). T790M was detected in the rebiopsy and in the 
peripheral blood after clinical progression (month 20) (Fig. 3C).
Case 3
Patient 16 presented with advanced non–small-cell 
lung cancer (TXN0M1b) diagnosed on pleural fluid cytol-
ogy and associated with an activating KRAS G12R mutation. 
Treatment was initiated (four cycles of pemetrexed and carbo-
platin) with an apparent clinical improvement and stable dis-
ease on Response Evaluation Criteria in Solid Tumors criteria. 
However, 9 weeks after the final cycle of chemotherapy, the 
patient progressed clinically although not radiologically. He 
was not well enough for further treatment.
DNA extracted from the pleural specimen was assayed 
using mdPCR for the KRAS G12R mutation (Fig. 4). Serial 
plasma analysis demonstrated an initial fall in both abso-
lute numbers of copies of the mutation detected and MAF 
with treatment. The re-emergence of the mutation at a 
significantly higher MAF correlated with marked clinical 
progression.
DISCUSSION
Lung cancer is a disease that generally presents late and 
for which many treatments are of limited efficacy. Standard 
follow-up consists of clinical and radiological monitoring. The 
noninvasive monitoring of tumor burden and specific mutational 
events is attractive to both clinicians and patients. In this study, 
we address the ability to monitor the response to intervention and 
the progression of disease on or off therapy using an inexpensive 
and simple protocol to perform surveillance of known mutations.
We show that mdPCR, using readily available fluores-
cently labelled probes, can be used to detect and accurately 
quantify mutational events in DNA derived from archived 
biopsies and plasma. We show that it can be used to track the 
response to both targeted therapy and more traditional che-
motherapy. Finally, we show that relapse/progression can 
be detected noninvasively and that the mechanism of resis-
tance can be inferred by the detection of resistance-causing 
mutations in the peripheral blood. These data illustrate how 
real-time treatment decisions may be informed by circulating 
biomarkers. The work is consistent with that of others showing 
A
B C
FIGURE 4.  Patient 16 presented with stage IV lung 
cancer diagnosed from pleural fluid cytology and 
was clinically genotyped as having the KRAS G12R 
mutation. DNA extracted from pleural fluid cells was 
reanalyzed using the mdPCR protocol giving a MAF 
of 28% (A). Serial plasma samples from patient 16 
were analyzed and a clear initial biomarker response 
to treatment demonstrated, with subsequent 
dramatic progression (B). Interestingly, the patient 
had been stable postchemotherapy at least until 
day 133, to a rapid clinical progression reflecting 
the biomarker rise, although there was not overt 
radiological progression. mdPCR, microdroplet digi-
tal polymerase chain reaction; MAF, mutant allele 
frequency.
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that serial analysis of tumor biomarkers in plasma may have 
an important role in the clinic.4–6
In case 1, the re-emergence of the EGFR exon 19 
deletion and the T790M resistance-conferring mutation 
was detected before any symptoms and before any evidence 
of radiological progression. Of note, subsequent imag-
ing investigations showed that the presumed index lesion 
had not progressed, but new nodules had appeared. In 
case 2, T790M was detected after 1 month off second-line 
 paclitaxel/carboplatin chemotherapy and again after disease 
progression on afatinib.
The role of ctDNA biomarkers in the management of 
lung cancer requires further exploration. In addition to the 
potential for documenting treatment response and the early 
detection relapse or progression, numerous other questions 
are raised. For example, these cases raise the issue of the 
relationship between ctDNA biomarkers and the degree of 
radiological response (partial versus complete) or the clini-
cal implications of biomarker persistence throughout various 
targeted and nontargeted therapeutic strategies.
Multiple platforms have been proposed for the analy-
sis of ctDNA, all with different attributes. Next generation 
sequencing-based protocols have important advantages in 
terms of sequencing power and the high level multiplex-
ing possible, meaning that genomic hotspots can be readily 
sequenced in an unbiased manner; but they are more complex 
protocols and are still relatively costly. There are a number of 
locus-specific PCR/probe-based approaches in which prese-
lected mutational events are interrogated.8,14
MdPCR is a simple protocol with easily interpreta-
ble results that may be ideally suited to tracking specific 
 mutations in serial blood samples. Although this article was 
in preparation, Oxnard et al.14 reported a similar approach 
in a larger series using custom-designed primers/probes 
with different performance characteristics. For example, the 
“off-the-shelf ” EGFR19del probe used in this study may 
well be more specific. Primer/probe selection for optimum 
specificity will be key to any translation of this approach to 
the clinic.
These studies, showing similar results and efficacy in 
different populations, suggest that mdPCR-based analysis 
of ctDNA has the potential to aid rational clinical decision 
making in lung cancer patients with known mutational geno-
types and that prospective validation trials of this approach 
are warranted.
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